approval of brentuximab vedotin for cd30 mycosis fungoides
Published 2 years ago • 166 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
3:48
phase ii study of brentuximab vedotin chp in patients with ptcl with less than 10% cd30 expression
-
2:39
the significance of cd30 in the response to brentuximab vedotin for patients with t-cell lymphoma
-
2:44
brentuximab vedotin and chp for ptcl: upcoming phase ii trial
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl
-
2:28
checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to allosct for hl
-
3:24
results from the breselibet trial of brentuximab vedotin chemotherapy for r/r hodgkin lymphoma
-
17:27
me/cfs mitochondria research presentation by ronald w. davis, phd
-
3:12
[bionote] vcheck m: workflow of whole blood sample cartridge
-
7:49
mycosis fungoides (cutaneous t-cell lymphoma): 5-minute pathology pearls
-
0:47
overview of the phase iii enhance trial schema
-
4:48
an insight into the management of cytopenias in mf
-
1:03
insights into the cartitude-6 trial: rationale and design
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:11
genomic testing can help identify patient risk factors and guide clinical decision-making
-
4:21
hovon 141/vision trial update: mrd-guided venetoclax ibrutinib treatment for r/r cll
-
2:19
feasibility of biomarker-driven strategy in high-risk lbcl: final results from nordic phase ii study
-
3:54
a case study from the ecog-e1910 trial: early blinatumomab treatment in all
-
1:21
cd20/cd3 bispecific antibodies in r/r dlbcl: glofitamab and epcoritamab
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
2:12
social media – a useful tool for hematological research
-
2:23
dw-mri and serum biomarkers to assess tumor burden and bone loss in multiple myeloma